Gem­phire IPO stag­gers in­to the mar­ket, reap­ing $30M

It takes a re­al­ly good sto­ry to com­plete a suc­cess­ful biotech IPO these days. The key el­e­ments: Hot tech­nol­o­gy, deep pock­et in­vestors, and a hefty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.